FDA Panel Backs First mRNA Flu Shot for Older Americans

The technology that helped the world beat COVID-19 is about to revolutionize how we fight the flu.

Federal health advisers unanimously voted Thursday to recommend approval of the first mRNA flu vaccine for the U.S. market. Moderna's new shot, called mFlusiva, could reach older Americans by this winter's flu season if the FDA gives final approval by early August.

This matters because tens of thousands of Americans die from influenza every year, with older adults facing the highest risk. But this new vaccine offers something current flu shots can't: speed.

The mRNA technology that won a Nobel Prize allows manufacturers to brew new doses much faster than traditional methods. If the shape-shifting flu virus suddenly mutates mid-season, companies could quickly update the vaccine to match the new strain.

"Having this technology available puts us in a better position to be prepared for emerging strains in the future," said Dr. Flor Munoz-Rivas of Texas Children's Hospital, one of the FDA advisers who reviewed the data.

The results from testing look promising. In a study of 40,000 people age 50 and older, Moderna's mRNA vaccine reduced flu cases by 27% compared to existing vaccines. A smaller study in people 65 and older showed the shot generated strong immune protection compared to high-dose flu vaccines already on the market.

"The vaccine looks very promising," said FDA adviser Dr. Anna Durbin of Johns Hopkins University, noting the compelling immune response data.

Moderna is seeking full approval for ages 50 to 64 and conditional authorization for those 65 and older while conducting additional studies. The company plans a massive follow-up study involving 400,000 seniors over two flu seasons.

The shot does cause temporary reactions like injection site pain, fever, headache, tiredness and body aches. These side effects happen somewhat more often than with current flu shots, but the FDA notes this is typical of mRNA vaccines.

Dr. Hayley Gans, a Stanford Medicine pediatrician and FDA adviser, explained these reactions are actually positive signs. "Your immune system is responding," she said, emphasizing the importance of explaining this to people who get vaccinated.

The Ripple Effect

Moderna's ability to quickly manufacture vaccines that closely match circulating flu strains could prevent thousands of hospitalizations in older Americans each year. Severe flu cases typically surge when the annual flu shot doesn't match the virus well.

Right now, flu vaccine recipes get chosen months earlier than COVID-19 shots, leaving more time for mismatches if the virus mutates. This faster mRNA technology could close that gap and save lives.

Moderna is also studying the vaccine in younger adults and plans research in teenagers this fall, potentially expanding protection across age groups.

A new generation of flu protection is almost here, bringing hope for better defenses against a virus that's challenged us for generations.